132 related articles for article (PubMed ID: 11474885)
1. [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use].
Dubin M; Fernandez Villamil SH; Stoppani AO
Medicina (B Aires); 2001; 61(3):343-50. PubMed ID: 11474885
[TBL] [Abstract][Full Text] [Related]
2. Activation of c-Jun NH2-terminal kinase and subsequent CPP32/Yama during topoisomerase inhibitor beta-lapachone-induced apoptosis through an oxidation-dependent pathway.
Shiah SG; Chuang SE; Chau YP; Shen SC; Kuo ML
Cancer Res; 1999 Jan; 59(2):391-8. PubMed ID: 9927052
[TBL] [Abstract][Full Text] [Related]
3. Peroxiredoxin 1 knockdown potentiates β-lapachone cytotoxicity through modulation of reactive oxygen species and mitogen-activated protein kinase signals.
He T; Banach-Latapy A; Vernis L; Dardalhon M; Chanet R; Huang ME
Carcinogenesis; 2013 Apr; 34(4):760-9. PubMed ID: 23239746
[TBL] [Abstract][Full Text] [Related]
4. beta-Lapachone-induced apoptosis in human prostate cancer cells: involvement of NQO1/xip3.
Planchon SM; Pink JJ; Tagliarino C; Bornmann WG; Varnes ME; Boothman DA
Exp Cell Res; 2001 Jul; 267(1):95-106. PubMed ID: 11412042
[TBL] [Abstract][Full Text] [Related]
5. Mu-calpain activation in beta-lapachone-mediated apoptosis.
Tagliarino C; Pink JJ; Reinicke KE; Simmers SM; Wuerzberger-Davis SM; Boothman DA
Cancer Biol Ther; 2003; 2(2):141-52. PubMed ID: 12750552
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.
Dong Y; Bey EA; Li LS; Kabbani W; Yan J; Xie XJ; Hsieh JT; Gao J; Boothman DA
Cancer Res; 2010 Oct; 70(20):8088-96. PubMed ID: 20940411
[TBL] [Abstract][Full Text] [Related]
7. Induction of CDK inhibitors (p21(WAF1) and p27(Kip1)) and Bak in the beta-lapachone-induced apoptosis of human prostate cancer cells.
Don MJ; Chang YH; Chen KK; Ho LK; Chau YP
Mol Pharmacol; 2001 Apr; 59(4):784-94. PubMed ID: 11259623
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of p53, induction of Bax and activation of caspases during beta-lapachone-mediated apoptosis in human prostate epithelial cells.
Choi YH; Kim MJ; Lee SY; Lee YN; Chi GY; Eom HS; Kim ND; Choi BT
Int J Oncol; 2002 Dec; 21(6):1293-9. PubMed ID: 12429980
[TBL] [Abstract][Full Text] [Related]
9. beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
Gupta D; Podar K; Tai YT; Lin B; Hideshima T; Akiyama M; LeBlanc R; Catley L; Mitsiades N; Mitsiades C; Chauhan D; Munshi NC; Anderson KC
Exp Hematol; 2002 Jul; 30(7):711-20. PubMed ID: 12135668
[TBL] [Abstract][Full Text] [Related]
10. Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone.
Bentle MS; Reinicke KE; Dong Y; Bey EA; Boothman DA
Cancer Res; 2007 Jul; 67(14):6936-45. PubMed ID: 17638905
[TBL] [Abstract][Full Text] [Related]
11. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
12. X-ray repair cross-complementing protein 1 (XRCC1) loss promotes β-lapachone -induced apoptosis in pancreatic cancer cells.
Zheng Y; Zhang H; Guo Y; Chen Y; Chen H; Liu Y
BMC Cancer; 2021 Nov; 21(1):1234. PubMed ID: 34789190
[TBL] [Abstract][Full Text] [Related]
13. Cancer therapy with beta-lapachone.
Pardee AB; Li YZ; Li CJ
Curr Cancer Drug Targets; 2002 Sep; 2(3):227-42. PubMed ID: 12188909
[TBL] [Abstract][Full Text] [Related]
14. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
[TBL] [Abstract][Full Text] [Related]
15. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
16. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 protects against beta-lapachone-mediated caspase 3 activation and apoptosis in human myeloid leukemia (HL-60) cells.
Planchon SM; Wuerzberger-Davis SM; Pink JJ; Robertson KA; Bornmann WG; Boothman DA
Oncol Rep; 1999; 6(3):485-92. PubMed ID: 10203579
[TBL] [Abstract][Full Text] [Related]
18. Yeast cytotoxic sensitivity to the antitumour agent β-lapachone depends mainly on oxidative stress and is largely independent of microtubule- or topoisomerase-mediated DNA damage.
Ramos-Pérez C; Lorenzo-Castrillejo I; Quevedo O; García-Luis J; Matos-Perdomo E; Medina-Coello C; Estévez-Braun A; Machín F
Biochem Pharmacol; 2014 Nov; 92(2):206-19. PubMed ID: 25241291
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of poly(ADP-ribose) polymerase activation attenuates beta-lapachone-induced necrotic cell death in human osteosarcoma cells.
Liu TJ; Lin SY; Chau YP
Toxicol Appl Pharmacol; 2002 Jul; 182(2):116-25. PubMed ID: 12140175
[TBL] [Abstract][Full Text] [Related]
20. Trypanosoma cruzi: death phenotypes induced by ortho-naphthoquinone substrates of the aldo-keto reductase (TcAKR). Role of this enzyme in the mechanism of action of β-lapachone.
Garavaglia PA; Rubio MF; Laverrière M; Tasso LM; Fichera LE; Cannata JJB; García GA
Parasitology; 2018 Aug; 145(9):1251-1259. PubMed ID: 29400267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
